Lilly, Boehringer launch Glyxambi; German watchdogs do a turnabout on Provenge;

@FiercePharma: ICYMI yesterday: Regeneron chief nabs $42M, but he'll have to pay his own club fees this year. Article | Follow @FiercePharma

@EricPFierce: ICYMI: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce

@CarlyHFierce: GSK, U.K. 'hopeful' they can strike a Bexsero price deal soon. FierceVaccines story | Follow @CarlyHFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim rolled out their combo diabetes drug Glyxambi--which melds the SGLT-2 drug Jardiance and the DPP-4 inhibitor Tradjenta--in the U.S. market. Release

> German cost watchdogs did an about-face on the Dendreon prostate cancer treatment Provenge, agreeing to back the drug after the company offered new cost-effectiveness data. Report

> Novo Nordisk ($NVO) won final European approval for its new obesity drug Saxenda, a reformulated version of its diabetes blockbuster Victoza; launches will begin later this year. Release

> Johnson & Johnson ($JNJ) prevailed in a patent fight over the ADHD med Concerta, when a judge knocked down claims from a doctor claiming to be a co-inventor of the drug. Report (reg. req.)

> Hungary's Richter will pay a dividend of 33 forints per share on 2014 earnings, down from 57 forints previously, the company said in its annual meeting announcement. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Foundation Medicine reveals C-suite and board metamorphosis. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Does the FDA overregulate devices? Experts weigh in. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: French researchers harness wireless monitors to track drug-resistant bacteria. Story | Follow @EmilyWFierce

> Nearly 10,000 GE, Siemens MRI machines under FDA recall. Story

> Abiomed gains after FDA finally approves tiny heart pump. Report

> Startup raises Series A to launch interactive, holographic surgical imaging software. News

Biotech News

@FierceBiotech: Video: Is this a biotech bubble? Watch | Follow @FierceBiotech

@JohnCFierce: Daiichi Sankyo starts layoff drive with 16% cuts at HQ. FiercePharma report | Follow @JohnCFierce

@DamianFierce: We asked @FierceBiotech readers whether biotech is in a bubble or a sustainable boom. Here's what they said | Follow @DamianFierce

> Bristol, Sanofi and Novartis lead pack in big year for blockbusters. More

> Google's Calico widens its R&D net with QB3 partnership. Article

> Bristol-Myers picks up an autoimmune project as Novo quits the field. Report

Drug Delivery News

> Bacteria deliver molecule to gut to suppress hunger and ward off weight gain. Report

> Clearside's novel eye drug delivery tech shows promise in latest clinical trial. More

> 3D printing will enable creation of delivery devices on demand. Item

> Developer of men's health drug with novel delivery tech secures $1M+ in seed financing. Story

> Maker of microspheres for local delivery of radiation suffers clinical trial setback. Article

Pharma Manufacturing News

> India to invest in infrastructure that drugmakers can share. Item

> Deals for Actavis, Teva plants put G&W in the spotlight; CEO says its culture is its beacon. Editor's corner

> Cypriot company targets Vietnam for generic expansion. More

> Norway's Weifa bets growth on separate API biz. Story

> Chinese company balks on reopening Boehringer plant. Report

Pharma Asia News

> South Korea tells Bayer to divest oral contraceptives business. Report

> China FDA approves first proton carbon ion therapy for Siemens device. Item

> Sun winds up Ranbaxy deal. More

> Daiichi Sankyo starts layoff drive with 16% cuts at HQ. Article

> China FDA approves first proton carbon ion therapy for Siemens device. Item

And Finally... Drug-resistant tuberculosis could kill 75 million people by 2050, a new report says. Report

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.